Richard A Larson
Overview
Explore the profile of Richard A Larson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
366
Citations
29430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeidner J, Sallman D, Recher C, Daver N, Leung A, Hiwase D, et al.
Blood
. 2025 Feb;
PMID: 40009500
Patients with TP53-mutated acute myeloid leukemia (AML) have an extremely poor prognosis, necessitating new treatments. The global, randomized, phase 3 ENHANCE-2 trial evaluated the anti-CD47 monoclonal antibody magrolimab plus azacitidine...
2.
Pyzer A, Dillon L, Sharon E, Karrison T, Zha Y, Fulton N, et al.
Blood Adv
. 2025 Feb;
PMID: 39928953
We conducted a multi-center, open-label, randomized phase II study to assess the efficacy of Nivolumab as maintenance therapy for patients with AML in first complete remission (CR) or CR with...
3.
Luskin M, Yin J, Lozanski G, Curran E, Malnassy G, Mrozek K, et al.
Cancer
. 2025 Feb;
131(4):e35750.
PMID: 39916320
Background: Acute lymphoblastic leukemia (ALL) in adults is aggressive, with long-term outcomes impacted by treatment resistance and toxicity. CD52 is expressed in most cases of B- and T-lineage ALL. Alemtuzumab,...
4.
Platzbecker U, Larson R, Gurbuxani S
Hemasphere
. 2025 Feb;
9(2):e70083.
PMID: 39897085
As a consequence of rapidly developing genetic technologies and advances in the understanding of the pathogenesis of acute myeloid leukemia (AML), the classification of AML has moved gradually from a...
5.
Ozga M, Nicolet D, Mrozek K, Walker C, Blachly J, Kohlschmidt J, et al.
Am J Hematol
. 2024 Sep;
99(11):2236-2240.
PMID: 39283025
No abstract available.
6.
Lin C, Patel A, Huo D, Karrison T, Van Besien K, Godwin J, et al.
Blood Adv
. 2024 Sep;
8(22):5735-5743.
PMID: 39250708
Myelofibrosis (MF) in the chronic phase is a challenging disease to treat, and conventional treatment options are geared toward symptom palliation. In this prospective, multicenter, phase 2 trial, 21 patients...
7.
Dohner H, DiNardo C, Appelbaum F, Craddock C, Dombret H, Ebert B, et al.
Blood
. 2024 Aug;
144(21):2169-2173.
PMID: 39133932
The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an...
8.
He G, Belmont E, Karrison T, Stock W, LaBelle J, Kosuri S, et al.
Ann Transl Med
. 2024 Jun;
12(3):49.
PMID: 38911560
Background: The somatic mutation of fms-like tyrosine kinase 3 () in acute myeloid leukemia (AML) is associated with increased risk of relapse and lower survival rates. FLT3i as maintenance after...
9.
Kumar S, Larson R, Stecklein S, Reddy J, Debeb B, Amos R, et al.
bioRxiv
. 2024 Jun;
PMID: 38854130
Purpose: Inhibiting HMG-CoA reductase with simvastatin prevents breast cancer metastases in preclinical models and radiosensitizes monolayer and stem-like IBC cell lines . Given the extensive use of simvastatin worldwide and...
10.
Hochhaus A, Wang J, Kim D, Kim D, Mayer J, Goh Y, et al.
N Engl J Med
. 2024 May;
391(10):885-898.
PMID: 38820078
Background: Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term therapy with high efficacy and safety. Asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket, may offer better...